Angiotensinogen messenger RNA (mRNA) levels were measured in the brain (hypothalamus, lower brain stem, cerebellum), liver, kidneys, and adrenal glands of rats made hypertensive by ligation of the aorta between the renal arteries. We also measured renin mRNA in the kidneys of these renal hypertensive rats. The early phase of hypertension (day 6) was associated with significant increases in plasma renin activity and levels of circulating angiotensin II. The circulating renin-angiotensin system was not activated in the later phase of hypertension (day 24). Angiotensinogen mRNA levels were elevated in the lower brain stem of hypertensive rats at both stages of hypertension. In contrast, angiotensinogen mRNA levels in the hypothalamus were increased only at day 6 after aortic ligation. Decreased levels of angiotensinogen mRNA were observed in the cerebellum in both the early and later phases of the hypertension. Angiotensinogen mRNA levels in the adrenal gland below the ligature fell in the early phases but rose in the later phases of hypertension. Renin mRNA levels of the ischemic kidney remained elevated at both the early and later phases, whereas in both ischemic and nonischemic kidneys, levels of angiotensinogen mRNA remained below sham values throughout the period of study. These results indicate differential expression of renin-angiotensin system mRNAs in tissues of renal hypertensive rats. The differential changes in the expression of angiotensinogen mRNA over the course of development and maintenance of renal hypertension suggest that factors in addition to angiotensin II are important in modulating the expression of renin-angiotensin system genes. A increase in the activity of the renin-angiotensin system (RAS) has long been suspected to contribute to the pathogenesis of arterial hypertension. '-3 The causes of the activated RAS remain unclear. In these studies, we investigated whether increased expression of the messenger RNA (mRNA) that encode components of the RAS was either the basis for, or associated with, early overactivity of the RAS and the increased arterial pressure in the aortic ligation model of renal hypertension. We have shown that plasma renin activity (PRA) was elevated in the early but not the later stages of hypertension caused by aortic ligation. 4 -6 After total occlusion of the aorta, the kidney below the ligature becomes ischemic and secretes large amounts of renin. Administration of either renin or angiotensin converting enzyme (ACE) inhibitors and angiotensin II (Ang II) receptor antagonists reverses the elevations in pressure produced by renal ischemia. Because tissues contain local RAS, 9 -12 these local systems may contribute significantly to the hemodynamic and vascular changes associated with the evolution of hypertension. Therefore, we undertook to characterize the contribution of specifically expressed RAS mRNA in this hypertensive rat model. We evaluated the expression of angiotensinogen and renin mRNA in peripheral organs and in several brain regions of rats developing high blood pressure after aortic ligation to gain an insight into factors that modulate the expression of the RAS in hypertension.
A increase in the activity of the renin-angiotensin system (RAS) has long been suspected to contribute to the pathogenesis of arterial hypertension.'- 3 The causes of the activated RAS remain unclear. In these studies, we investigated whether increased expression of the messenger RNA (mRNA) that encode components of the RAS was either the basis for, or associated with, early overactivity of the RAS and the increased arterial pressure in the aortic ligation model of renal hypertension. We have shown that plasma renin activity (PRA) was elevated in the early but not the later stages of hypertension caused by aortic ligation. 4 -6 After total occlusion of the aorta, the kidney below the ligature becomes ischemic and secretes large amounts of renin. Administration of either renin or angiotensin converting enzyme (ACE) inhibitors and angiotensin II (Ang II) receptor antagonists reverses the elevations in pressure produced by renal ischemia. 7 ' 8 son, NJ.) was introduced into a carotid artery under light anesthesia (1% halothane) on either the fifth or the 23rd day after either aortic ligation or sham operation. Blood pressure and heart rate were recorded after 24 hours while rats remained calm in a holding cage. Blood pressure was recorded with a solid strain transducer (MP-150, Micron Instruments Inc., Los Angeles, Calif.) connected to the indwelling catheter. Heart rate was electronically computed by a tachometer from the pulse of the arterial pressure waveform. Both signals were displayed on a multichannel polygraph (model 2000, Gould, Cleveland, Ohio). Rats were killed by decapitation on either the sixth or 24th day after aortic ligation. These times were chosen on the basis of previous experiments that determined the hemodynamic and hormonal stages of this model of hypertension. 4 - 6 Samples of blood (3.5 ml) were taken through the carotid arterial catheter before animals were decapitated. Thereafter, the brain (hypothalamus, lower brain stem, i.e., medulla oblongata, and cerebellum), liver, kidneys, and adrenal glands were removed immediately, carefully freed of surrounding fat and connective tissue, and snap frozen on dry ice. Tissue samples were stored at -80^C until RNA was extracted.
Biochemical Assays
One milliliter of arterial blood was collected into prechilled glass tubes containing 50 p\ of 0.5 M ammonium ethylenediaminetetraacetic acid (NH,-EDTA) solution for determinations of plasma angiotensinogen concentration and PRA.
14 Plasma Ang II immunoreactivity was determined in samples of arterial blood (2 ml) poured into prechilled glass tubes containing 100 y\ of an inhibitor cocktail shown to eliminate in vitro processing of angiotensin peptides. 15 Plasma creatinine concentration was measured from an aliquot of the blood (0.5 ml) collected into the tube containing NH,-EDTA. After centrifugation at 4°C, plasma samples were stored at -20°C until assay. Plasma angiotensinogen and PRA were determined by radioimmunoassay, as reported previously. 16 Plasma Ang II was measured by a radioimmunoassay, also described elsewhere. 15 Plasma creatinine was determined using a Technicon analyzer.
Complementary DNA Clones and Preparation of Phosphorus-32-Labeled Probes
Double-stranded DNA hybridization probes 17 were labeled with [ a -^d A T P using a nick translation kit (Boehringer Mannheim GmbH, Mannheim, FRG). Plasmid or inserts included rat angiotensinogen complementary DNA (cDNA), rat renin cDNA, and HeLa /3-actin cDNA. Specific activities of the probes were 2.2-3.0X10 8 dpm/jtg. A synthetic oligodeoxynucleotide [ACGGTATCTGATCGTCTTCGAACC] complementary to rat 18S ribosomal RNA 18 was labeled with [y.KpjdAXP using polynucleotide kinase (Boehringer Mannheim Corporation, Indianapolis, Ind.). Because ribosomal RNA is the predominant constituent in total cellular RNA and 18S RNA represents a fixed proportion of ribosomal RNA, hybridization to the oligodeoxynucleotide can be used to normalize total cellular RNA samples.
Extraction of RNA
Each tissue was weighed and immediately homogenized in guanidine isothiocyanate RNA isolation buffer, as described previously. 1719 The concentration of total cellular RNA was determined by measuring the absorbance at 260 nm.
Northern Blot Analysis
Aliquots of total RNA (25 /xg) were lyophilized and denatured at 65°C for 10 minutes in 50% deionized formamide, 6% formaldehyde, 10% glycerol, 20 mM boric acid, 0.2 mM Na 2 -EDTA, and bromphenol blue. The denatured RNA was separated by electrophoresis in a 0.8% agarose gel containing 3% formaldehyde, 20 mM boric acid, and 0.2 mM Na 2 -EDTA. RNA was transferred to nylon membranes (Gene Screen, New England Nuclear, Boston) by capillary action in 25 mM phosphate buffer. The membranes were baked in a vacuum oven at 80°C for 2 hours and prehybridized at 42°C for at least 2 hours in a solution containing 50% deionized formamide, 20 mM PIPES, 800 mM NaCl, 2 mM EDTA, 0.5% SDS, and 0.1 mg/ml denatured salmon sperm DNA. The membranes were then hybridized at 42°C for 12-16 hours with a fresh hybridization solution containing lxlO 6 cpm/ml 32 P-labeled cDNA probe. After hybridization, membranes were washed sequentially in 2xSSC (lxSSC=0.15 M sodium chloride, 0.015 M sodium citrate, pH 7.0), 0.1% SDS at room temperature, lxSSC, 0.1% SDS at 50°C, and O.lxSSC, 0.1% SDS either at 50°C (renin or /3-actin) or 60°C (angiotensinogen) to remove the unhybridized probe. Blots were exposed to XAR-5 x-ray film (Eastman Kodak Co., Rochester, N.Y.) with two intensifying screens (Cronex, E.I. du Pont de Nemours & Company, Wilmington, Del.). Radioactive standards (ARC-146 carbon-14 standard; American Radiolabeled Chemicals Inc., St. Louis, Mo.) were included to determine relative optical densities. Several exposures were obtained to achieve optimal autoradiography signals that could be visualized within the range of optical gray densities provided by U C standards. Video densitometric analysis of autoradiographs used the National Institutes of Health image analysis software IMAGE (version 1.28).
For quantification of relative levels of expression of angiotensinogen or renin mRNA, autoradiographic signals for angiotensinogen and renin were standardized to signals determined from /3-actin mRNA in each preparation to control for amounts of RNA loaded per lane. 17 RNA from each animal was quantified separately. In Table 1 , we show densitometric values obtained from lower brain stem RNA samples as an example of our analytic methods. Six rats were used in each of four groups (sham on day 6, aortic ligation [AL] on day 6, sham on day 24, and AL on day 24). We chose one animal randomly from each group (for example, sham 1 and AL 1 on day 6 and sham 1 and AL 1 on day 24) and analyzed them as one RNA set. This produced six sets of RNA. These six sets of RNA were run on the same gel, hybridized with the same probe at the same time, and exposed on the same film. For densitometric measurements, autoradiographic signals were measured as densitometric units in each set of RNA. For quantification of relative levels of expression of angiotensinogen or renin mRNA, the autoradiographic signals were standardized to signals determined from /}-actin mRNA in each preparation to control for amounts of RNA loaded per lane. We assigned the sham groups the value of 100% and expressed changes in relative levels of mRNA in the AL groups by dividing AL values by sham values.
To assess interassay precision, we performed Northern blot analysis twice in the same 24 samples and compared the differences in values using Student's t test and correlation analysis between the first and second results. The probability value was >0.05; thus, there was no difference between the two results. The data were significantly correlated (r=0.972, p<0.001). For intraassay variations, the coefficient of variation was determined to be 2.1%.
Slot Blot Analysis
Total cellular RNA from each experimental sample was aliquoted into six serial dilutions (4,000-125 ng). The RNA was denatured at 65°C for 10 minutes in formaldehyde and applied to a nitrocellulose membrane in a Bio-Rad slot blot apparatus (Bio-Rad Laboratories, Richmond, Calif.). The membrane was baked under vacuum at 80°C for 2 hours and prehybridized at 42°C for at least 2 hours in a solution containing 50% deionized formamide, 5xSSC, lxDenhardt's solution, 50 mM NaHPO«, and 250 ^tg/ml denatured salmon sperm DNA. The membrane was then hybridized at 42°C for 12-16 hours with fresh hybridization solution containing 1x10' cpm/ml a-32 P-labeled cDNA angiotensinogen probe. After hybridization, the membrane was washed sequentially under the same conditions as the Northern blot. In hybridizations with y-^P-labeled oligodeoxynucleotide probe, the membrane was hybridized at 37°C for 3 hours in a solution containing 6xSSC, lxDenhardt's solution, 0.1% SDS, 0.05% sodium pyrophosphate, 100 ^g/ml denatured salmon sperm DNA, and then hybridized at 37°C for 12-16 hours with a fresh hybridization solution containing 6xSSC, lxDenhardt's solution, 0.1% SDS, 0.05% sodium pyrophosphate, 20 Mg/ml yeast transfer RNA, lxlO 5 cpm/ml -y-^P-labeled oligodeoxynucleotide probe, and 400 -fold excess unlabeled oligodeoxynucleotide. After hybridization, the membrane was washed in 3xSSC, 0.1% SDS to remove unhybridized probes. Hybridization signals of angiotensinogen mRNA were plotted as a function of 18S ribosomal RNA oligodeoxynucleotide hybridization, and the slope of the linear regression line was Right kidney (mg/100 g body wt)
Left adrenal gland (mg/100 g body wt)
Right adrenal gland (mg/100 g body wt)
Sham taken as the relative concentration of angiotensinogen mRNA. The means of the slopes were calculated for each group, and statistical differences between groups were tested as described below.
Statistical Analyses
Data are expressed as mean±SEM Differences between experimental and sham groups at 6 and 24 days were evaluated by both the Student's t test and one-way ANOVA followed by Duncan's multiple range test. Two-way ANOVA was used to assess differences between 6-and 24-day groups. Univariate correlation analysis was used to examine relations between mRNA levels and other parameters. The criterion for statistical significance was p<0.05.
Results

Characteristics of Aortic Ligation Hypertension
The mean arterial pressure of aortic-ligated rats was consistently above that recorded in sham-operated rats (p<0.01) throughout the duration of the experiments (Table 2) . Heart rate was not changed, but weight gain was reduced in hypertensive rats when compared with sham-operated controls (/?<0.05). Table 2 also shows that hypertension was associated with hypertrophy of the kidney above the ligature (/?<0.01), whereas the weight of the ischemic kidney fell to values below those recorded in sham-operated rats at day 24 (/><0.001). There were no significant changes in the weight of the adrenal glands of hypertensive rats when compared with sham-operated rats. Moreover, renal function was preserved; plasma levels of creatinine in hypertensive rats were not different from those measured in sham-operated rats (Table 3) .
Hypertension was associated with an early increase in the activity of the circulating RAS followed at 24 days by a return toward normal levels (Table 3) . During the early phases of hypertension, hyperreninemia was associated with increases in the plasma concentration of immunoreactive (ir) Ang IT (p<0.05) but no changes in plasma angiotensinogen concentration. Mean arterial pressure was significantly correlated with plasma irAng II (r=0.810, p<0.05). In contrast, the later phase of renal hypertension was accompanied by a reduction in plasma irAng II to levels that approached normal. Similar reductions in PRA were also found at this time. The concentration of plasma angiotensinogen in 24-day hypertensive animals was significantly reduced (p<0.01). In addition, plasma levels of angiotensinogen were inversely correlated with levels of renin activity (r= -0.916,p<0.05).
Effects of Aortic Ligation on Expression of Angiotensinogen mRNA
Levels of angiotensinogen mRNA were quantified in three brain regions (Figure 1 ). Six days after aortic ligation, the relative levels of expression of angiotensinogen mRNA increased by 50% in the hypothalamus (p<0.05) and by 30% in the lower brain stem (p<0.05). In contrast, angiotensinogen mRNA levels decreased by 33% in the cerebellum (p<0.01). Twenty-four days after ligation, there was a further increase in the expression of angiotensinogen mRNA to 80% in the lower brain stem (p<0.05), whereas angiotensinogen mRNA levels in the hypothalamus returned to control values ( Figure 1 ). In the cerebellum, the expression of angiotensinogen mRNA remained reduced by an average of 30% (p<0.01). Changes in renal angiotcnsinogen mRNA expression are shown in Figure 2 (upper panel). Both the ischemic and nonischemic kidneys showed significant decreases in angiotensinogen mRNA throughout the early and later phases of hypertension (p<0.01). The greatest decrease in the levels of angiotensinogen mRNA was observed in the ischemic kidney of 6-day hypertensive rats. These changes were accompanied hy significant increases in the levels of renin mRNA in the kidney below the ligature (p<0.01) (Figure 2, lower panel) .
We also measured the levels of angiotensinogen mRNA in adrenal glands above and below the ligature glands below the ligature, angiotensinogen mRNA levels decreased by 45% in the early phase (p<0.01). At day 24, the levels of angiotensinogen mRNA in the adrenal gland below the ligature in aortic-ligated rats increased by 150% (p<0.05). At day 24, 0-actin mRNA levels in the adrenal gland below the ligature showed a small (34%) but significant (p<0.05) increase in aorticligated rats compared with sham-operated rats. There were no significant differences in /3-actin mRNA between sham-operated and aortic-ligated rats at days 6 and 24 for ah" other tissues examined. Thus, even when consideration was made for the minor changes in the standard, the data showed that the majority of changes in angiotensinogen mRNA ratio are attributable to specific changes in gene expression. An additional finding was uncovered when we compared the angiotensinogen mRNA signals in adrenal glands at days 6 and 24 in sham-operated rats. Figure 3 illustrates that angiotensinogen mRNA in the adrenal gland below the ligature of 24-day sham-operated rats was decreased by 65% compared with values obtained at day 6 (p<0.01) after standardization to 0-actin mRNA. In contrast, angiotensinogen mRNA of the adrenal gland at day 24 in aortic-ligated rats increased by 180% over the values found at day 6. To confirm the differences we observed in expression of angiotensinogen mRNA in sham-operated rats in the adrenal glands, we reanalyzed these samples by slot blot analysis, standardizing angiotensinogen mRNA levels to 18S ribosomal RNA. The expression of angiotensinogen mRNA levels in the adrenal gland on day 24 in sham animals was significantly decreased compared with day 6 (slope values: 1.06±0.041 on day 6 [n=4] versus 0.88+0.028 on day 24 [n=4], p<0.05). These data showed that there may be a developmental decrease in angiotensinogen mRNA in rat adrenal glands. This change appears to be specific for the adrenal gland because there were no differences in angiotensinogen mRNA levels in the liver of sham-operated rats at these same time points ( ligation on the mRNA encoding angiotensinogen and /J-actin. Direct determination of the actual magnitude of change in aortic-ligated rats awaits studies using 18S ribosomal RNA as a standard. Figure 4 shows relative changes in hepatic angiotensinogen mRNA in aortic-ligated rats. Levels of angiotensinogen mRNA in the liver showed no consistent 2.8 kb - changes with respect to sham-operated animals at days 6 and 24 after ligation. Tables 4 and 5 illustrate relations among angiotensinogen mRNA, renin mRNA, and other variables during the evolution of renal hypertension. Mean arterial pressure showed a positive correlation with renin mRNA in the kidney below the ligature at day 6 but not at day 24 (Table 4) . Plasma irAng II correlated with increases in the expression of renin mRNA of the ischemic kidney during both the early ( hypertension (Table 5) . Hepatic angiotensinogen mRNA correlated with the changes in angiotensinogen mRNA in the hypothalamus at both days 6 and 24 but with the values measured in the ischemic kidney at day 6 only. During the established phase of hypertension, the increases in angiotensinogen mRNA in the lower brain stem correlated with the decreases in the expression of the gene in cerebellar tissue (data not shown).
Other correlations were not statistically significant (Tables 4 and 5).
Discussion
The present study showed a differential regulation of angiotensinogen mRNA both in the renin-dependent and in the non-renin-dependent phases of experimentally induced renal hypertension caused by aortic ligation. Small but statistically significant changes in RAS mRNAs were observed during both the development and maintenance of aortic ligation-induced renal hypertension. The magnitude of changes in mRNAs in this study is sufficient to produce comparable changes in protein production. Results from earlier studies in adrenalectomized rats support our conclusion. In the rat, diencephalon angiotensinogen mRNA decreased by 28-45%, 20 whereas in a separate study, brain tissue angiotensinogen protein concentrations decreased by 24-42%. 21 These data suggest that small changes in angiotensinogen mRNA are reflected in changes of the same magnitude in angiotensinogen in rat brain; thus, the 30-50% changes in angiotensinogen mRNA that occurred in our study are adequate to influence local tissue production of angiotensinogen. In addition, because the RAS encompasses multiple enzymes in addition to renin, the summation of relatively small effects at many different targets could produce a large cumulative effect on the final end products of the pathway, for example, local concentrations of Ang II.
We examined the responses of tissues expressing both high-and low-abundance levels of angiotensinogen mRNA. Results from our Northern blot analyses indicate the following order of abundance: liver/brain/ adrenal gland/kidney, in agreement with earlier studies. 22 - 23 Our findings also confirm the suggestion that synthesis of angiotensinogen in peripheral tissues undergoes differential regulation. 17 It would be logical to expect that the early rise in plasma Ang II favored enhanced expression of angiotensinogen mRNA, based on results of in vitro and in vivo studies 24 -26 ; however, during the early phase of hypertension when circulating levels of Ang II were elevated, levels of hepatic angio- Multiple regression analysis of percent changes in angiotensinogen and renin messenger RNA (mRNA) in aortic-ligated rats at day 6 after operation.
*R values; statistical significance atp<0.05. Above, above the ligature; below, bekw the ligature; ir, immunoreactive; Ang IL angiotensin II. Multiple regression analysis of percent changes in angiotensinogen and renin messenger RNA (mRNA) in aortic-ligated rats at day 24 after operation.
*R values; statistical significance atp<0.05. Above, above the ligature; below, below the ligature; ir, immunoreactive; Ang n, angiotensin II.
tensinogen mRNA did not increase. Furthermore, no significant correlation was found between changes in liver angiotensinogen mRNA levels and plasma Ang II concentrations. Interestingly, hepatic levels of angiotensinogen mRNA remained within normal values even when plasma levels of angiotensinogen were reduced during the chronic phase of aortic Ugation hypertension. This observation suggests that the normal feedback mechanisms by which plasma Ang II levels regulate hepatic angiotensinogen mRNA production were altered or superseded by the effects of other factors that intervene in the pathological state of high blood pressure. Kohara et al 17 recently analyzed regulation of rat tissue angiotensinogen mRNA produced in response to a 5-day infusion of either subpressor or pressor amounts of Ang II given either intravenously or into a brain ventricle. These studies demonstrated that both peripheral and central Ang II administration stimulate increased expression of angiotensinogen mRNA in the liver and brain. The finding that aortic ligation hypertension causes no enhanced expression of angiotensinogen mRNA in peripheral tissues suggests that control mechanisms in addition to Ang II exert regulatory effects on the hepatic and extrahepatic expression of the angiotensinogen gene and angiotensinogen mRNA. At present, the identify of these factors remains largely unknown. Herrmann and Dzau 23 suggested that the synthesis of hepatic angiotensinogen is under the tonic inhibitory control of renin. This hypothesis agrees with observations that nephrectomy 27 -28 augments hepatic production of angiotensinogen. In 6-day aortic-ligated rats, both PRA and renal renin mRNA rose above values found in sham-operated controls. Therefore, it is possible that the counterbalancing effects of inhibition by renin and stimulation by Ang II may account for the failure of hepatic and extrahepatic angiotensinogen mRNA to rise in response to increases in circulating levels of Ang II. An alternative explanation is that inflammatory responses, acting through acute-phase response elements present in the angiotensinogen gene, 29 play a major role in determining angiotensinogen mRNA levels in the liver under these experimental conditions.
Aortic ligation hypertension increased the expression of angiotensinogen mRNA in the brain. This suggests an important role for the brain RAS in the pathogenesis of hypertension. Analysis of angiotensinogen mRNA in the regions of the brain participating in the regulation of endocrine secretions and neuronal control of cardiovascular function clearly showed that control of gene expression is region specific. In our experiments, angiotensinogen mRNA levels were transiently increased in the hypothalamus, persistently elevated in the lower brain stem, and consistently reduced in the cerebellum. Moreover, changes in angiotensinogen mRNA in the lower brain stem correlated with mean arterial pressure during both the early and later phases of aortic ligation hypertension. Comparative correlations with blood pressure were not found for levels of angiotensinogen mRNA in either the hypothalamus or the cerebellum. The medulla oblongata contains high levels of angiotensinogen mRNA that may be produced in localized regions of the dorsal medulla oblongata adjacent to the area postrema and the vagal solitarii complex. 30 Both the medulla oblongata and the hypothalamus are enriched with Ang II receptors and are sites at which circulating and cerebrospinal fluid Ang II acts to modulate baroreceptor reflexes.
31
- 32 The increased expression of angiotensinogen mRNA in the medulla oblongata is consistent with the possibility that a local brain RAS participates in the evolution of renal hypertension. 32 The mechanisms that account for the increased expression of the angiotensinogen mRNA in the medulla oblongata remain to be determined. Both Ang II and glucocorticoids are candidates. 17 -32 Furthermore, whether the increase in angiotensinogen mRNA in the lower brain stem normally plays a central role in hypertension needs to be studied. This finding, however, may explain the previously observed association of increased blood pressure with decreasing levels of PRA that was noted both in this 5 and in another model of renovascular hypertension. 33 In the early phase of hypertension, adrenal angiotensinogen mRNA was reduced, whereas 24 days after aortic ligation, there appeared to be an increase in levels of angiotensinogen mRNA in the adrenal gland adjacent to the ischemic kidney when compared with sham controls. The apparent increase in angiotensinogen mRNA of the adrenal glands below the ligature at day 24 is the result of both increased angiotensinogen mRNA and small increases in levels of 0-actin mRNA. The rats we used were growing; therefore, the changes we found in regulation of both of these mRNAs may have been developmental. In sham-operated rats, angiotensinogen mRNA levels in the adrenal glands were decreased on day 24 compared with day 6. Liver angiotensinogen mRNA levels, on the other hand, did not change with time. A possible interpretation of this finding is that there are tissue-specific developmental changes in angiotensinogen mRNA expression. However, because £-actin mRNA expression did not change in other tissues, cumulative effects on /3-actin mRNA expression as a result of development and aortic ligation appear to be reflected only in adrenal tissue. It is unlikely that ischemia alone accounts for the change because in the early stage of hypertension, angiotensinogen mRNA of the adrenal glands below the ligature was reduced, and /3-actin mRNA expression was unchanged. Other studies by us (unpublished results from our laboratory) suggest that mRNA in adrenal glands may be more responsive to stimulation than in other tissues. 17 Hypertension was associated with reduced levels of kidney angiotensinogen mRNA. Here again, any potential effects of Ang II, glucocorticoids, or both, appear to have been circumvented by the action of other unknown inhibitory factors. Because only the kidney above the ligature is exposed to the high blood pressure, it is unlikely that pressure itself altered levels of kidney angiotensinogen mRNA; thus, neither plasma Ang II levels nor blood pressure fully accounts for regulation of renal angiotensinogen mRNA expression. It is important to note that most of the previous data that determined the action of the major stimuli for the synthesis and release of angiotensinogen were obtained in isolated preparations, cell culture studies, or cell-free translation systems. 24 -26 It is largely unknown how these stimuli function in an integrated fashion in normal and pathological states. 26 In aortic-ligated rats, increased renin mRNA in the ischemic kidney may contribute to the initiation of hypertension. The strong correlation of blood pressure with renal renin mRNA in the early phase of aortic ligation-induced hypertension and the lack of correlation of blood pressure with renal renin mRNA in the later phase suggest that in the early phase, kidney renin is primarily responsible for the hypertension, but with time, the contribution of the renal RAS declines. This would be consistent with local RAS other than the kidney assuming more important roles in the later phase of hypertension. In our study, we found evidence for an increased RAS in the later stage of hypertension (day 24); at this time, angiotensinogen mRNA levels were elevated in the medulla oblongata.
In the nonischemic kidney, renin mRNA was unchanged. This was unexpected in the early phase when circulating levels of Ang II were high, because Ang II is known to exert a negative feedback on kidney renin mRNA. Thus, this may be another example in which Ang II regulation of RAS components is superseded by other factors. Our studies do not directly address the question of the contribution that renal angiotensinogen mRNA makes to hypertension or the synthesis of angiotensinogen and Ang II peptides in the kidney. A possible means of regulating local production of peptides in the ischemic kidney may result from the decreased angiotensinogen mRNA in association with the increased renin mRNA In this instance, there may be no net change in kidney tissue angiotensin peptide levels.
The inclusion of measurements of plasma levels of renin activity, angiotensinogen, and Ang II concentrations allowed precise characterization of the activity of the circulating RAS system, in which the angiotensinogen gene encodes the only known substrate. Past studies have used renin activity to characterize the degree of activation of the RAS in this form of hypertension. 4 " 6 Inclusion of measurements of irAng II allows us to confirm that aortic ligation caused an increase in the activity of the circulating RAS at the early phase. During the later stages of hypertension caused by aortic ligation, levels of both irAng II and PRA returned to normal levels. Our results provide evidence for tissue-and regionspecific changes in angiotensinogen mRNA production that were not fully reflected in changes in plasma angiotensinogen concentration. We found that plasma angiotensinogen concentrations did not correlate with changes in liver angiotensinogen mRNA. This finding was unexpected, because previous studies have indicated that angiotensinogen released into the circulation by the liver reflects de novo synthesis. Because our measurements reflect steady-state levels of mRNA, it is possible that there could be changes in liver angiotensinogen mRNA stability that would contribute to the lack of correlation between plasma angiotensinogen and angiotensinogen synthesis and turnover. Our studies showed a tissue-and region-specific effect of hypertension on the expression of extrahepatic angiotensinogen mRNA within organs that are implicated in the pathogenesis of hypertension. Of all tissues examined, only in the lower brain stem were the levels of angiotensinogen mRNA consistent with the concept that the local tissue RAS contributes to hypertension. In other tissues, including the kidney and adrenal gland at the early phase, the contributions of local RAS were reduced.
In conclusion, our data uncover new possibilities and raise some important questions regarding the involvement of local tissue angiotensin systems as mechanisms that account for the hemodynamic, hormonal, and structural adaptations associated with the development of experimental renal hypertension.
